c-Met Inhibition | c-Met Inhibitor Review

Research Area

Cat.No.	Product Name	Information	Publication	Customer Review
S1111	Foretinib (GSK1363089, XL880)	XL880 (GSK1363089, EXEL-2880) is an ATP-competitive inhibitor of MET and KDR with IC50 of 0.4 nM and 0.9 nM, respectively.	(3)	(1)
S1070	PHA-665752	PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM.	(5)	(1)
S1080	SU11274	SU11274 is a selective Met inhibitor with IC50 of 10 nM.	(8)	(1)
S1094	PF-04217903	PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM.	(1)	(1)
S1112	SGX-523	SGX-523 is a selective Met inhibitor with IC50 of 4 nM.	(4)	(1)
S1561	BMS 777607	BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively.		(1)
S2753	ARQ 197 (Tivantinib)	ARQ-197 is a novel and selective human c-Met inhibitor with IC50 of 0.1 μM.
S7067	EMD 1214063	EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 6 nM.
S2859	Golvatinib (E7050)	E7050 is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM, respectively.
S2788	INCB28060	INCB28060 is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM.
S2774	MK-2461	MK-2461 is a potent inhibitor of c-Met, Ron, Flt1/3, PDGFRβ, Mer and FGFR1/2/3 with IC50 of 2.5 nM, 7 nM, 10 nM/22 nM, 22 nM, 24 nM and 65 nM/39 nM/50 nM, respectively.